Quantum Biopharma (NASDAQ:QNTM – Get Free Report) and Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.
Profitability
This table compares Quantum Biopharma and Arcutis Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum Biopharma | N/A | -436.23% | -150.85% |
| Arcutis Biotherapeutics | -4.29% | -10.26% | -4.30% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Quantum Biopharma and Arcutis Biotherapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quantum Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Arcutis Biotherapeutics | 1 | 2 | 5 | 0 | 2.50 |
Volatility & Risk
Quantum Biopharma has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500.
Valuation & Earnings
This table compares Quantum Biopharma and Arcutis Biotherapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quantum Biopharma | N/A | N/A | -$26.17 million | ($8.72) | -0.36 |
| Arcutis Biotherapeutics | $376.07 million | 8.09 | -$16.14 million | ($0.14) | -175.21 |
Arcutis Biotherapeutics has higher revenue and earnings than Quantum Biopharma. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
1.2% of Quantum Biopharma shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Arcutis Biotherapeutics beats Quantum Biopharma on 10 of the 13 factors compared between the two stocks.
About Quantum Biopharma
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
